Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and PCSK9 Inhibitor for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
This is a multicenter, prospective, randomized controlled study to evaluate the effectiveness and safety of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and PCSK9 inhibitor in the treatment of patients with pMMR/MSS locally advanced middle and low rectal cancer.
Epistemonikos ID: 896960a5bef05aa271a76fec7e7d18be6134c74d
First added on: May 15, 2024